NASDAQ:GERN   Geron Corporation
Shares of Geron have been on the retail trader’s radar following a series of news and industry catalysts. The late-stage biopharmaceutical company specializes in developing treatments for hematologic malignancies. At the beginning of the year, the company announced positive top-line results from its IMerge Phase 3 trials of imetelstat.
t’s the company’s candidate in targeting such hematologic malignancies and, in this case, showed a response in patients with lower-risk myelodysplastic syndromes. The trial met its primary endpoint for efficacy and showed “statistically significant and clinically meaningful” benefits versus placebo. It also released headlines showing that the company plans on hiring a senior leadership team specifically focused on the commercial launch of imetelstat in the U.S.

What do analysts think about GERN stock? If you look at the rating from B. Riley, you’ll see it has Geron set with a Buy rating and a $5 target. Based on recent closing prices of $3.40, that’s 47% higher at the moment.
Buy with the target price above 5.5 and keep stop loss at 2.9 and trade this is peeny stocks there is high probability of profit and trade accordingly to your risk and rewards,

Thankyou if you like my idea then please like and follow me on

Best Regards,
Rahul Pal
(Full Time Trader & Investor)

Join Free telegram

Contact us for High Accuracy above 85% Paid Trading Advisory & Portfolio Management Services & Learning Programmes.
Whatsapp:- +919560604457

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.